Skip to main content
Naveen Pereira, MD, Cardiology, Rochester, MN, Mayo Clinic Hospital - Rochester

NaveenLPereiraMD

Cardiology Rochester, MN

Heart Failure & Transplantation, Cardiovascular Disease Genetics

Professor of Medicine, Mayo Clinic

Dr. Pereira is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Pereira's full profile

Already have an account?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Cardiovascular Disease, 1998 - 1999
  • Brown University
    Brown UniversityFellowship, Cardiovascular Disease, 1995 - 1998
  • University of Connecticut
    University of ConnecticutResidency, Internal Medicine, 1992 - 1995
  • Topiwala National Medical College
    Topiwala National Medical CollegeClass of 1991

Certifications & Licensure

  • WI State Medical License
    WI State Medical License 2014 - 2025
  • SC State Medical License
    SC State Medical License 1999 - 2025
  • MN State Medical License
    MN State Medical License 2007 - 2024
  • CT State Medical License
    CT State Medical License 1995 - 1998
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Member Sigma Xi
  • Poster Prize Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 2012
  • Clinical Immunology and Immunotherapeutic Program Award Mayo Clinic, 2010
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention  
    Naveen L Pereira, Verghese Mathew, Charles Cagin, Amir Lerman, Charanjit Rihal, JAMA
  • Genotype-guided dosing of Vitamin K antagonists  
    Pereira NL, Rihal CS, Weinshilboum RM, N Engl J Med., 5/1/2014
  • The possible impact of lack of ethnic and geographical diversity on the association of MTHFR mutations, homocysteine levels and heart disease outcomes  
    Pereira NL, Ball-Berry JE, Green El, Heart, 12/4/2013
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Genetic Association Study of Circulating Galectin-3 in the General Community Identifies a Variant Associated with Myocardial Infaction. (Poster)
    Pereira NL, American Heart Association Scientific Sessions 2014, Chicago, IL, 11/1/2014
  • Role of vad therapy for patients with restrictive cardiomyopathy: improving outcomes for a lethal disease.
    Grupper A, Joyce LD, Stulak JM, Schettle SD, Gerber Y, Topilsky Y, Pereira NL, Edwards BS, Daly RC, Park SJ, Kushwaha SS, J Heart Lung Transplant, 4/1/2014
  • Genetic association study of circulating Galectin-3 in the general community identifies a variant associated with myocardial infarction.
    Pereira N, Scott C, Jenkins G, Robinson D, Tosakulwong N, Burnett J, Weinshilboum R, Redfield M, Circulation, 1/1/2014
  • Join now to see all

Lectures

  • Cardiovascular Pharmacogenomics 2014: Right Drug for the Right Patient 
    Chicago, IL - 11/1/2014
  • Antiplatelet Therapy and Pharmacogenomics for the Clinician 
    Vina del Mar, Chile - 8/1/2014
  • Cardiovascular Pharmacogenomics: Giving the Right Drug to the Right Patient 
    Ottawa, Canada - 5/1/2014
  • Join now to see all

Other

  • COAG and EU-PACT: The pharmacogenetics of warfarin dosing. 
    Pereira NL, Medscape
    12/5/2013
  • Ventricular Assist Device. (Television Interview) 
    Pereira NL, WCSC Channel 5, CBS Affiliate
    11/1/2004
  • CHF - Treatment Options. (Television Interview) 
    Pereira NL
    WCSC Channel 5, CBS Affiliate - 6/1/2004
  • Join now to see all

Authored Content

  • Genotyping to Guide Clopidogrel Treatment: An in-Depth Analysis of the TAILOR-PCI TrialSeptember 2020
  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionAugust 2020
  • Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionAugust 2020
  • Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
  • Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
  • Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
  • Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
  • Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant RecipientsFebruary 2018
  • Spectrum of Restrictive and Infiltrative Cardiomyopathies Part 1 of a 2-Part SeriesJanuary 2018
  • Join now to see all

Press Mentions

  • Learning the Ropes of Clinical Trials to Bring Cures to Patients
    Learning the Ropes of Clinical Trials to Bring Cures to PatientsMay 16th, 2023
  • 10 Significant Mayo Clinic Center for Individualized Medicine Studies of 2021
    10 Significant Mayo Clinic Center for Individualized Medicine Studies of 2021January 12th, 2022
  • New Mayo Clinic Biorepository Provides for Critical Need
    New Mayo Clinic Biorepository Provides for Critical NeedJuly 8th, 2021
  • Join now to see all

Grant Support

  • Clinical Implementation of Clopidogrel Pharmacogenetics- TAILOR PCI trialNHLBIPresent

Committees

  • Vice Chair Publications Committee, Functional Genomics and Translational Biology - AHA

Professional Memberships

Hospital Affiliations